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Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system
with a disabling progressive course. Chronic cerebrospinal venous insufficiency (CCSVI) has recently been described
as a vascular condition characterized by restricted venous outflow from the brain, mainly due to blockages of the
internal jugular and azygos veins. Despite a wide variability among studies, it has been found to be associated with
MS. Data from a few small case series suggest possible improvement of the clinical course and quality of life by
performing percutaneous balloon angioplasty (PTA) of the stenotic veins.
Study design and methods: This is a multicenter, randomized, parallel group, blinded, sham-controlled trial to
assess the efficacy and safety of PTA. Participants with relapsing remitting MS or secondary progressive MS and a
sonographic diagnosis of CCSVI will be enrolled after providing their informed consent. Each participant will be
centrally randomized to receive catheter venography and PTA or catheter venography and sham PTA. Two primary
end points with respect to efficacy at 12 months are (1) a combined end point obtained through the integration of
five functional indicators, walking, balance, manual dexterity, bladder control, and visual acuity, objectively
measured by instruments; and (2) number of new brain lesions measured by T2-weighted MRI sequences.
Secondary end points include annual relapse rate, change in Expanded Disability Status Scale score, proportion of
patients with zero, one or two, or more than two relapses; fatigue; anxiety and depression; general cognitive state;
memory/attention/calculus; impact of bladder incontinence; and adverse events. Six hundred seventy-nine patients
will be recruited. The follow-up is scheduled at 12 months. Patients, treating neurologists, trained outcome
assessors, and the statistician in charge of data analysis will be masked to the assigned treatment.
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Discussion: The study will provide an answer regarding the efficacy of PTA on patients’ functional disability in
balance, motor, sensory, visual and bladder function, cognitive status, and emotional status, which are meaningful
clinical outcomes, beyond investigating the effects on inflammation. In fact, an important part of patients’
expectations, sustained and amplified by anecdotal data, has to do precisely with these functional aspects.
Trial registration: Clinicaltrials.gov NCT01371760
Keywords: Multiple sclerosis, Chronic cerebrospinal venous insufficiency, Percutaneous transluminal angioplasty,
Functional disabilityBackground
Multiple sclerosis (MS) is a chronic inflammatory demye-
linating disease of the central nervous system (CNS) with a
progressive course. Although the cause of MS is unknown,
it is regarded as a complex disease that results from the
combined effect of unidentified environmental factors and
susceptibility genes. In western countries, it represents the
second most common cause of disability in young adults,
with onset usually occurring in the third or fourth decade
of life. MS has an incidence of about 4 to 4.5 per 100.000
every year, an average prevalence of 83 per 100,000 in
Europe and a female-to-male ratio of about 3:1 [1].
MS has a chronic course that evolves over 30 to 40
years. The clinical phenotypes include relapsing-remitting
MS (RRMS), secondary progressive MS (SPMS), primary
progressive MS (PPMS) and progressive relapsing MS
(PRMS) [2]. The development of a progressive course is
by far the major route to permanent long-term disability,
and it supervenes in about 80% of patients with RRMS by
age 20 to 25 years. After age 15 to 18 years, about 50% of
patients need assistance to walk, are confined to a wheel-
chair or have died, but there is substantial variation [3].
There are currently several pharmacological treatments
approved for RRMS, but only one agent (interferon β-1b)
has been approved in Europe (but not by the U.S. Food
and Drug Administration (FDA)) for the SPMS form [4].
First-line treatments for RRMS patients are interferon β-1a
(IFN-β-1a) and IFN-1b and glatiramer acetate. The effect
of these treatments is a moderate reduction in relapse rate
and accumulation of disability at 1 to 2 years’ follow-up
[5]. There is evidence of no effect of these treatments for
patients with SPMS [6] and inconclusive evidence for
those with PPMS [7]. Side effects of these treatments are
common, including influenza-like symptoms, injection site
reactions, headache, depression and fatigue. Hematological
toxic effects include hemoglobin reduction, leukopenia,
lymphocytopenia, thrombocytopenia and increased liver
enzymes [5-7].
Mitoxantrone, natalizumab or fingolimod are second-line
treatments for patients who have failed to respond to the
first-line therapy. Mitoxantrone is moderately effective in
reducing disability progression and relapse rate in patients
with RRMS, PRMS and SPMS at short-term follow-up(2 years), but there is a long-term risk of therapy-related
leukemias and cardiotoxicity [8]. Natalizumab has been
shown to be consistently effective in reducing the risk of
relapses and disability progression after 2 years of treat-
ment, but it increases the risk (not yet definitively
assessed, but greater than 1 per 1,000 after 2 years of
treatment) of progressive multifocal leukoencephalopathy
[9]. Fingolimod was the first drug to gain approval as an
oral treatment by the FDA and the European Medicines
Agency (EMA) for reducing relapse rate, but it can cause
serious herpetic infections [10].
There is currently no available pharmacological treat-
ment with a good profile of safety and tolerability that is
able to change, surely and meaningfully, the natural
course of MS. Other biologic agents have recently been
evaluated in phase II clinical trials for MS and seem to
be more effective than interferons and glatiramer [11],
but more phase III trials are needed to provide conclu-
sive evidence of their efficacy and safety.
A recent hypothesis suggests that the presence of sten-
osis of the internal jugular vein (IJV) and/or azygos veins
that restricts normal blood flow from the brain and
spinal cord may be an important factor in the pathogen-
esis of MS [12,13]. The multifocal perivenous inflamma-
tion or demyelination in the CNS is postulated to be a
consequence of a breakdown of the blood–brain barrier
due to elevated transmural pressure, followed by
erythrocyte, plasma and iron extravasation, thus result-
ing in damage to the immune tolerance and setting off a
cascade of inflammatory events and immune responses
that can persist over time [14]. Were this hypothesis ten-
able, repairing venous stenosis and reestablishing correct
venous flow from the brain toward the heart could have
therapeutic effects, especially if the intervention was per-
formed early. This condition has been named “chronic
cerebrospinal venous insufficiency” (CCSVI) and is pos-
tulated to be congenital and genetically determined.
CCSVI, as defined by Zamboni et al., is diagnosed with
combined extracranial and transcranial echo color Doppler
(ECD) radiography when two or more of five established
parameters are present [12]. In 100% of the MS cases
examined by Zamboni and colleagues, at least two of these
alterations were found, as compared to 0% among healthy
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seases [12]. Since publication of this first study, several
articles have been published on the prevalence of CCSVI
in patients with or without MS. To collect all the avai-
lable information on CCSVI, we have updated (through
May 2012) the results of a previous published meta-
analysis [15]. The included studies were conducted in
Italy, the United States, Germany, Poland, Jordan and
Iran [12,16-29]. The results (Figure 1) indicate a statisti-
cally significant association between CCSVI and MS
(odds ratio = 4.90; LC 95% = 1.86 to 12.90). However,
the body of evidence is highly heterogeneous (I2 = 85%)
and thus inconclusive. The heterogeneity can be ascribed
to various factors, including low-quality studies, mainly
due to small sample sizes, inadequate study design and
setting, absence of blindedness, varying accuracy of the
ECD, including equipment, parameters, probes, techniques
used and examiners’ experience.
Zamboni et al. [30] reported the results of an open
study of endovascular treatment for CCSVI on 65 MS
patients who had undergone percutaneous transluminal
angioplasty (PTA) to widen the veins. The results of
PTA were safe. Patients with RRMS (n = 35) had fewer
relapses, and their MS functional composite (MSFC)
scores significantly improved at 18 months after the
intervention compared with baseline. Patients with
SPMS (n = 20) or PPMS (n = 10) showed little improve-
ment in MSFC score. All patients had improvement of
physical and mental health as measured by the MS
Quality of Life–54 questionnaire at 18-month follow-up.
A high incidence (47%) of restenosis in the IJV was
reported at 18 months [30]. In a case series of 24
patients, 6 patients had a relapse of clinical symptoms
within 1 to 2 months of the procedure, although it was
reported that they felt better than before the procedureFigure 1 Meta-analysis of diagnosis of chronic cerebrospinal venous
Zamboni criteria in patients with multiple sclerosis (MS)) versus healt[31]. In a case series of 31 MS patients with CCSVI, PTA
was performed in the azygos vein in 90% (28 of 31) of
patients and in both the left and right IJVs in 77% (24 of 31).
Scores on the Modified Fatigue Impact Scale (MFIS) signifi-
cantly improved from preoperative values, and the positive
trend was maintained at 1 year [32]. In a retrospective case
series of 167 patients affected by MS and CCSVI who
underwent PTA, 67% of patients reported subjective ameli-
oration regarding nonspecific symptoms [33]. In a case–con-
trol study, eight patients had PTA in addition to medical
therapy (immediate treatment group (ITG)), whereas seven
had treatment with PTA after 6 months of medical therapy
alone (delayed treatment group (DTG)). No adverse events
occurred. After PTA, a significant improvement in func-
tional score compared with baseline was found (P < 0.02).
The annualized relapse rate was 0.12% in the ITG group
compared with 0.66% in the DTG (P = ns). Magnetic
resonance imaging (MRI) demonstrated a trend for
fewer T2 lesions in the ITG (P = 0.081), corresponding
to a 10% decrease in the ITG compared with a 23% in-
crease in the DTG over the first 6 months of the study.
At 1 year, there was a restenosis rate of 27% [34].
A case series of 495 PTA procedures in 461 patients
reported restenosis requiring reintervention in 11 cases [35].
A case series of 331 patients reported that 15 repeat proce-
dures were done for reocclusions following balloon angio-
plasty [36]. A case series of 247 procedures (229 primary
procedures and 18 secondary procedures due to restenosis)
in 231 patients reported that 2% of patients had symptom-
atic stenosis that required retreatment within 30 days [37].
Regarding the safety of the intervention, the study by
Petrov [35] reported vein dissection in 3% of procedures
(15 of 495), vein rupture (resolved by prolonged balloon
dilatation and stenting) in two patients and groin
hematoma in 1% of procedures (5 of 495). The sameinsufficiency (presence of at least two parameters according to
hy controls.
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(6 of 495). These included atrial fibrillation in four
patients (two resolved spontaneously and two resolved
following treatment with amiodarone) and ventricular
fibrillation (successfully treated) and ventricular tachy-
cardia (timing not reported) in one patient each. The
case series of 331 patients [36] reported transient cardiac
arrhythmia during the procedure, which was managed
pharmacologically in 2 patients. Local bleeding from the
groin requiring readmission to the hospital occurred in
four patients (including two patients with pseudoaneur-
ysms successfully treated with thrombin injection). One
patient had minor gastrointestinal bleeding requiring
hospitalization at 1 week. Surgical removal of the bal-
loon was required in one patient, and difficulty in re-
moving the balloon or delivery system occurred in four
patients. No deaths, cerebral strokes, severe bleeding or
injury to the nerves were reported.
The whole body of data shows that there is inconclu-
sive evidence on the efficacy of balloon angioplasty for
MS patients, mainly due to the observational design of
the few small case series and their high risk of bias [38].
The uncertainty surrounding CCSVI and PTA treatment
means that it should be dealt with only as part of a
properly designed randomized clinical trial. An official
position statement put forth by the “Consiglio Superiore
di Sanità,” the scientific advisory board of the Italian Min-
istry of Health, recommends that study investigators “look
at the prevalence and association of CCSVI with MS,” and
states that “any test to assess benefits and risk of the treat-
ment for CCSVI should only be carried out in the context
of randomized controlled trials which would avoid any
commercial conflict of interest” [39].
In March 2012, the National Institute for Health and
Clinical Excellence (NICE) released guidance on percutan-
eous venoplasty for chronic cerebrospinal venous insuffi-
ciency for multiple sclerosis, stating “Current evidence on
the efficacy of percutaneous venoplasty for CCSVI for MS is
inadequate in quality and quantity” and encouraging “further
research on percutaneous venoplasty for CCSVI for MS, in
the form of robust controlled clinical trials. Outcomes
should include clinical and quality of life measures” [38].
Design
Study objective
In this study, we aim to evaluate the efficacy and safety
of angioplasty of extracranial veins for patients with
RRMS or SPMS and CCSVI.
Trial design
This trial is a multicenter, parallel group, blinded, phase
III randomized controlled trial. The study flow chart is
shown in Figure 2. The participating MS centers and their
associated sonologic and angiographic units are accreditedby the National Health System and approved by an ac-
creditation commission appointed by the steering com-
mittee (SC) of the study. All the procedures are performed
by personnel accredited for the ECD diagnosis of CCSVI,
the venous angioplasty intervention and the measurement
of the primary and secondary end points. After central
random allocation to a treatment group, each subject will
undergo either a venous angioplastic procedure or a sham
procedure. Recruitment will last 12 months, and patients
will be followed up for 12 months (15 months in the event
that the last follow-up has to be delayed).
Participants and recruitment
All participants will be recruited at the participating Italian
MS centers according to the inclusion and exclusion
criteria reported in Table 1. Patients with RRMS or
SPMS with a diagnosis of CCSVI will be included.
The ECD diagnosis of CCSVI will be made according
to the Zamboni criteria reported in Table 2 [12]. All
included participants will provide a written informed
consent form that explains the details of the trial,
interventions and study protocol in accordance with
the principles of the Declaration of Helsinki and the
ICH E6 Guideline for Good Clinical Practice.
Interventions: venography and venous angioplastic
procedure, real or sham
Participants will undergo selective venography of the
lumbar vein, left renal vein, azygos vein, and IJV by
catheterization of the left iliac femoral venous axis to
evaluate for the presence and location of venous malfor-
mations. Participants randomized to venous angioplasty
will receive the intervention during the diagnostic veno-
graphy session. The anomalies of the main extracranial
cerebrospinal veins that interfere with normal blood out-
flow of brain parenchyma are reported in Table 3
[12,13,30]. Participants randomized to the sham procedure
will undergo venography and a simulated angioplasty. The
angiography room operators will simulate the procedure of
balloon angioplasty, describing to the participants what
they are doing at each step and letting them know what
they might feel, not forgetting to assure them that lack of
sensation is also normal. All patients will be administered a
prophylactic dose of low-molecular-weight heparin for the
following 3 weeks. Any arising complications (hematoma,
venous thrombosis or vessel rupture) will require reexami-
nation in the vascular diagnostic center.
The performance of a complete venographic proced-
ure exposes the patient to ionized radiation at an effi-
cacious dose, ranging from a minimum of 25 mSv to a
maximum of 50 mSv (dose comparable to a number
ranging between 1250 and 2500 chest X-rays). The dur-
ation of the procedure and the doses of radiation admi-
nistered to patients will be monitored during the study.
Table 1 Inclusion and exclusion criteria for trial participants
Inclusion criteria Exclusion criteria
(1) Age 18–65 years (1) Patients who have previously undergone an extracranial venous
angioplasty
(2) Patients who have received care for at least 2 years at the
enrolling center
(2) Patients treated with natalizumab, fingolimod, cladribine or
laquinimod within 3 months prior to screening
(3) MS defined according to McDonald’s criteria [40] with relapsing-
remitting (RRMS) or secondary progressive (SPMS) course
(3) Patients treated with botulinum toxin within 3 months prior to
screening
(4) At least one relapse in the 2 years before inclusion for RRMS (4) Patients with implanted infusion pumps or neurostimulators
within 3 months prior to screening
(5) CCSVI diagnosed by ECD according to the Zamboni criteria [12] (5) Use of experimental drug or participation in a clinical trial within
3 months prior to screening
(6) EDSS from 2 to 5.5 (6) Contraindications to venography: documented thrombophilia,
previous adverse reactions after administration of iodized contrast
medium or presence of pathological conditions that could favor
reactions to the introduction of contrast medium, that is, severe
renal insufficiency, hepatic insufficiency, cardiac insufficiency,
Walderstrom’s paraproteinemia or multiple myeloma
(7) Disease duration from diagnosis to study inclusion ≤10 years for
RRMS and ≤15 years for SPMS
7) Contraindications to MRI and/or its contrast medium
(8) Stable neurological condition without relapse for at least 30 days (8) Hemoglobin value ≤9 g/dl, leukocytes >11,000/μl, thrombocytes
<70.000/μl
(9) Patient not undergoing therapy, or undergoing disease-
modifying therapies without modification for at least 6 months
(9) Prothrombin time, activated partial thromboplastin time, creatinine
values outside laboratory reference ranges
(10) Written informed consent. (10) Monoclonal gammopathy or hypergammaglobulinemia (>21%)
(11) History of congenital or ischemic cardiopathy, arrhythmias,
conditions that can cause changes in motor and/or vision and/or
bladder and/or cognitive functions
(12) Current or previous radiotherapy performed for any reason
(13) Female subjects pregnant or lactating
(14) Patients unable to comply with the follow-up
Figure 2 Study flow chart.
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Table 2 Doppler parameters that detect five anomalous
venous hemodynamic criteria affecting cerebrospinal
venous returna
(1) Reflux-bidirectional flow constantly present in the IJV and/or
vertebral vein with the patient in both examination positions (sitting
and supine posture) in at least one of the three
landmarks (J1, J2, J3)
(2) Reflux-bidirectional flow in the intracranial veins: The presence
of intracranial venous reflux is diagnosed when there is reflux
on the Rosenthal’s vein and/or transverse sinus and/or cavernous
sinus and/or superior or inferior petrosus sinus
(3) B-mode and M-mode demonstration of intraluminal defects
(septa, valvular malformations, double-channel) and/or
cross-sectional area <0.3 cm2
(4) Absent flow in internal jugular veins and/or vertebral veins
after repeated deep inhalations with the patient in both
examination positions (sitting and supine) in at least one of
the three landmarks (J1, J2, J3). The finding of absence of flow
in only one body position becomes a useful criterion even if
reflux-bidirectional flow is found in the other position.
(5) Cross-sectional area of the IJV at J2 point greater in sitting
that in supine posture
aAs described by Zamboni [12]. At least two of the five anomalous venous
hemodynamic criteria must be present for the diagnosis of chronic
cerebrospinal venous insufficiency (CCSVI).
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sent form.
Primary end points
We identified two primary end points, one defined by a
combination of clinical parameters related to specificTable 3 Anomalies at catheter venography of the main
extracranial cerebrospinal veins that interfere with
normal blood outflow of brain parenchyma described in
patients with MSa
(1) Stenosis: any venous lumen reduction >50% or presence of a trans-
stenosis gradient, that is, higher pressure in the IJVs and/or azygos
vein compared to pressure in the superior vena cava or the
brachiocephalic trunk
(2) Septum/valve malformation
(3) Inversion of valve direction, twisting of a venous segment with
consequent stenosis, hypoplasia of a venous segment or agenesis
of a venous segment. In all these cases, angioplasty is not always
effective or cannot be done, but it will be reported to differentiate
complete from incomplete procedures.
(4) Anomalous presence of inverted flow with respect to the
physiological direction (for example, in supine position, azygos vein
that empties into the left renal vein instead of into the superior
vena cava; azygos vein that refluxes into the perivertebral plexus
with stasis)
(5) External compression, for example, aortic arch compressing the left
brachiocephalic trunk with stasis and/or reflux into the IJVs or the
vertebral veins; Cockett syndrome and hyperinflows into the lumbar
hemiazygos circulation. Such compressions cannot always be
treated with angioplasty, but they will be reported to differentiate
complete from incomplete procedures.
(6) Dysmorphic valve apparatus in presence of fixed membrane in the
M-mode test and/or absent flow and/or accelerated flow ≥90 cm/s
and/or reflux-bidirectional flow ≥1.5 seconds
aSee [12,13,30].functional deficits experienced by patients with MS and
the other one based on MRI findings, both measured 12
months after randomization.
Clinical end point
We will use a combined end point obtained through the in-
tegration of five functional indicators clinically meaningful
and measured with validated instrumental methods.
These are related to walking [41,42], balance [43], manual
dexterity [44], bladder control [45] and low-contrast visual
acuity [46]. Each patient, at 3, 6 and 12 months after
randomization, will undergo a reevaluation using the whole
battery of tests. On the basis of the published minimal real
difference [41-45], or the published clinically significant dif-
ference for low-contrast visual acuity [46], each function
will be classified as “improved/stable/worsened,” and the
combined evaluation of the five functions will lead to the
classification of the participant as improved/stable/wor-
sened/fluctuating according to the following criteria: (1)
improved patient, defined as the presence of significant im-
provement in one or more functions and stability in nonim-
proving functions; (2) worsened patient, defined as the
presence of worsening in one or more functions and stabil-
ity in nonworsening functions; (3) fluctuating patient,
defined as concomitant presence of improvement and wor-
sening in one or more functions; and (4) stable patient,
defined as the presence of stability in all functions.
Conditions interfering with the measurement of clinical end
point
In case of transient impairments hindering measurement of
one or more of the five functional tests contributing to the
primary outcome (for example, minor trauma of the leg
limiting walking and balance performances), the trouble-
some tests will be postponed until the next follow-up visit.
In case of irreversible impairment, the remaining functions
will be tested throughout the study. In the event that one
or more functions will not be measurable at the last follow-
up or at the 3-month extension follow-up, the Clinical End-
point Commission (CEC) will assign the patient to one of
the above categories, based on a critical data review blinded
to the treatment arm. At least three functions must remain
testable at the last follow-up; otherwise, the patient will be
classified as “worsened.” The classification of the clinical
end point will be carried out by the CEC, which will evalu-
ate blindly all of the documentation of each patient.
Brain MRI
T2-weighted brain MRI will be used to determine the
number of new brain lesions over the entire 1-year period.
The number of brain lesions will be defined as new or en-
larging lesions or lesions reappearing at the site of previ-
ously healed lesions on T2-weighted MRI scans. Reading
of the MRI will be performed by neuroradiologists in a
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The MRI examinations will be carried out at the partici-
pating centers in keeping with the technical protocol.
Secondary end points
Secondary end points at 12 months will be annual re-
lapse rate; changes in disability measured by the EDSS
score (0- to 10-point scale, where 0 is normal, 3 is mild
disability, 6 is cane requirement, 7 is wheelchair use and
10 is death due to MS) [47]; proportion of patients with
relapses, classified as 0, 1–2 or >2 relapses; proportion
of patients who will undergo angioplasty who present
with restenosis within 12 months afterward; MRI activity
at 12 months in angioplasty patients with or without re-
stenosis; fatigue measured using the Modified Fatigue
Impact Scale (M-FIS Questionnaire) [48]; anxiety and
depression measured using the Hospital Anxiety and
Depression Scale (HADS-A/D questionnaire) [49];
general cognitive state measured using the Montreal
Cognitive Assessment (MoCA test) [50]; memory/atten-
tion/calculus measured using the Paced Auditory Serial
Addition test (PASAT) [51]; impact of bladder incontinence
measured using the Overactive Bladder Questionnaire
(OABQ) [52]; and adverse events. A secondary objective is
to estimate the proportion of patients with CCSVI diag-
nosed by ECD and confirmed by venography.
Sample size
The study was designed by taking into account (1) the
need to include all patients who are potential candidates
for the therapeutic benefit of angioplasty and (2) the
need for a short enrollment period and a follow-up of 12
months. Since the two diagnostic categories (RRMS and
SPMS) will have different participant sizes and respon-
siveness, the statistical power will be different in the two
groups. Estimates of the treatment effect will be more
precise in the largest subgroup of RRMS. For the
patients with SPMS, the study will provide preliminary
information, possibly requiring an extension of recruit-
ment of SPMS subjects. The sample size calculation and
the definition of the analysis plan will be different for
the two types of patients.
Patients with RRMS
The sample size was estimated on the basis of the pri-
mary end point on MRI. We assume that the average
total number of MRI active lesions in the control group
is equal to 6 with a standard deviation of 7.6 [53]. The
intention-to-treat (ITT) analysis of 423 patients, allo-
cated into the two treatment arms according to a
randomization ratio of 1:2 (141 in the control arm and
282 in the experimental arm), will allow us to detect an
absolute mean reduction of 2.1 lesions with an α error
of 0.05 (two-sided likelihood ratio test (LRT)) and apower of 90% (power analysis based on 5,000 simula-
tions, assuming a negative binomial distribution). Thus,
we will be able to highlight a 1-year mean reduction
from 6 lesions in the control arm to 3.9 in the experi-
mental arm, which corresponds to a relative reduction
of 35%. Even in the presence of a higher level of variabil-
ity, with a standard deviation of nine lesions, our study
would have a power of 81%, to show as statistically sig-
nificant the same difference. This sample size will also
be able to show a reduction of at least 0.3 in the
annualized relapse rate with a power greater than 93%,
(0.6 vs. 0.9 in the control arm, α = 0.05, two-sided
LRT). The sample size of 423 patients is also adequate
for the evaluation of the combined clinical end point
with a 92% power or higher to detect a 15% increase
in the percentage of improved patients (with a 5% to
15% figure in the control arm, α=0.05, two-sided test
on proportions). To obtain a sample size of 423, a
total of 445 patients will be recruited (148 in the con-
trol arm and 297 in the experimental arm), to take
into account a 5% dropout rate, leading to nonevalua-
tion of the primary end point at 12 months.
Patients with SPMS
This combined clinical end point is being used, to the
best of our knowledge, for the first time in this trial.
Thus, the power of the study was calculated under vari-
ous scenarios concerning different values of the 12
months percentage of improvement in either group. The
main analysis concerns the probability of improvement,
considering the worsened, the stable and the fluctuating
conditions as failures. With an enrolment of 222 patients
allocated according to a randomization ratio of 1:2
(74 in control arm and 148 in experimental arm), power
is sufficient to detect, based on the ITT analysis, an ab-
solute improvement ranging from 15% to 25% (α = 0.05,
two-sided test on proportions), as shown in Table 4. In
order to obtain a sample size of 222, a total of 234
patients will be recruited (78 in the control arm and 156
in the experimental arm), taking into account a 5% of
drop-out due to lack of evaluation at 12 months.
Randomization and blinding
The randomization procedure will be defined by the
Data Coordination Center (DCC) and will be stratified
by participating center and disease course, RRMS or
SPMS, with variable length blocks. Responsibility for im-
plementation of the computerized randomization pro-
cedure will be assigned to the CRO. The randomization
lists will be delivered to the DCC member responsible
for quality before the beginning of recruitment. Alloca-
tion to treatment arms will be done centrally by web,
and the result on the treatment assigned will be reported
automatically in the database. Randomization will be
Table 4 Power calculation for different scenarios of
baseline values and deltas of the probability of
improvement at 1 year in the combined clinical end
point (intention-to-treat analysis)
Probability of improvement
at 1 year in the control group
Delta of improvement in the
experimental group
5% 10% 15%
15% 0.84 0.72 0.64
20% 0.97 0.92 0.87
25% 0.99 0.98 0.97
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surgeon responsible for the intervention.
Although the surgeons cannot be masked, because
they will be performing the intervention, the patient, the
treating neurologist, the outcome assessors (such as the
investigators who will measure the functional end
points), the two physiatrists of the Functional Endpoint
Committee, the neuroradiologist responsible for centra-
lized measurement of MRI and the statistician respon-
sible for data analysis will be masked to the assigned
treatment. In cases in which the treating neurologist
needs to open the code, for exceptional reasons of safety
or at authorities’ request, the neurologist will send the
request to the chairperson of the steering committee,
who may give consent to the opening of the code only
after careful consideration of the motivations.
Data collection
The scheduling of examinations and tests is reported in
Table 5. The treating neurologist will be responsible for
the overall medical management of patients, including
pharmacological treatment for MS, as well as scheduled
(every 3 months) and unscheduled follow-up visits. The
treating neurologist will advise patients to contact the
clinic at any time if new symptoms or complications
occur. At each visit, the treating neurologist will record
any new symptoms, any adverse events and theirTable 5 Scheduling of examinations and tests
Time Examinations and tests
−45 days
(maximum)
Clinical verification of eligibility, information to patient,
informed consent (must take place before the ECD
and blood tests), blood tests and ECD prescription
Performance of ECD, blood tests
−15 days
(maximum)
Baseline clinical visit, functional tests and MRI,
planning of angioplastic surgery (real or sham)
0 Randomization and angioplasty (real or sham)
+3 months Clinical visit and functional tests
+6 months Clinical visit, ECD, MRI and functional tests
+9 months Clinical visit
+12 months Clinical visit, ECD, MRI and functional testsmanagement and treatment decisions, including discon-
tinuation of pharmacological treatments.
All data will be securely stored in an electronic case
report form (e-CRF). Data access will be protected by
user name and password according to different profiles,
depending on the user. In particular, centers will have
access only to data relative to their own center, whereas
the center responsible for informatics infrastructure of
the CRO and the member of the DCC responsible for
quality will have online access to the entire database to
perform periodic quality checks. An electronic query
system, managed by the CRO monitor, will be available,
and every correction of original data will have to be
approved by the member of the DCC responsible for
data quality. The traceability of all data (original and
corrected) entered into the system will be guaranteed.
The research data will be stored for up to 7 years, in
compliance with any integrity issues that may arise from
any subsequent publications (Article 18, paragraph 1, of
the D.l. 200 dated 6 November 2007). Following that
time period, the data will be under the control of the
treating neurologist.
Adverse events
All subjects will be monitored throughout the study for
adverse events (AEs). Possible AEs related to this study
are (1) allergic reactions or hypersensitivity to the con-
trast medium (immediate or delayed), such as nausea,
vomiting (even prolonged), itching, hives, bronchial
spasm (3% of cases); (2) slight local pain (40% of cases)
or headache (10%) during dilatation of the veins; (3)
minor bleeding with local hematoma at the injection site
(5% of cases), nausea and lowering of arterial pressure
(0.2%) during cannulation of the femoral vein; and (4)
postoperative headache. Possible serious AEs (SAEs) are
(1) allergic reactions or hypersensitivity to the contrast
medium (immediate or delayed), such as hypertensive
shock, pulmonary edema or cardiorespiratory arrest (1
patient in 1,000); and (2) venous thrombosis or ruptur-
ing of the vein with postoperative hemorrhage (3% to 4%
of cases). Unexpected AEs can also occur as a result of
technical difficulties during the venographic and angio-
plastic procedures. All AEs or SAEs will be reported to
the Safety Surveillance Unit/Institutional Review Board
(SSU/IRB) that approved the protocol, unless otherwise
required and documented by the SSU/IRB. All AEs or
SAEs will be reported in the e-CRF.
Statistical analyses
The DCC will be responsible for the statistical analysis
at the end of the study. Analysis will be performed
blinded to the treatment allocation. The main analysis
will be conducted according to the principles of ITT,
separately on the two subpopulations (RRMS and
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be retained in the original randomized arm. The second-
ary analysis will be run per protocol (PP) and will take
into consideration all randomized patients who were
positive (true CCSVI) also at the time of venography. It
is expected that the false-positives will be at most 10%.
Dropout cases (missing data at both the 12-month as-
sessment and the 3-month extension) will be excluded
from both the ITT and the PP analyses. We expect ≤5%
dropout cases. The impact of missing data will be evalu-
ated by sensitivity analysis. Both the ITT and PP analyses
will also be conducted across the whole study sample
(RRMS and SPMS).
Patients with RRMS
In this group of patients, the evaluation of the treatment
effect on the MRI primary end point (average number of
lesions on MRI at 1 year) will be performed using a LRT,
assuming a negative binomial model (α = 5%, two-sided
test). This comparison will also be evaluated using a re-
gression model, adjusting for some important factors, that
is, time from diagnosis of MS disease, concomitant treat-
ments and EDSS at baseline. A descriptive analysis will
also be conducted on the components of this primary end
point, considering separately the treatment effect on T1
active lesions and on new or enlarging T2 lesions. The ef-
fect of the treatment will also be assessed on the clinical
end point, comparing the proportions of patients classified
as “improved,” as defined in the “primary end point” sec-
tion (α = 5%, two-sided test on proportions). The relapse
rate (secondary end point) in the two treatment groups
will be compared by means of a LRT, assuming a Poisson
model (also adjusting for the same factors considered for
the primary end point). The Poisson model assumptions
will be assessed, and, in the event of evidence of overdis-
persion, alternative models that relax these assumptions
will be considered (that is, mixed-effects Poisson model).
Patients with SPMS
For the patients with SPMS subpopulation, the primary
analysis will be carried out with a test on proportions,
comparing the proportion of subjects in the two arms
who will be classified as “improved” with respect to the
clinical end point (α = 5%, two-sided test). A multivari-
ate analysis based on a logistic regression model will be
carried out, taking into account relevant factors, such as
gender, time from MS diagnosis, concomitant treatments
and EDSS at baseline. A secondary analysis of treatment
effect will also be performed by comparing the distribu-
tion of each category of the combined end point in the
two treatment groups. The treatment effect on each sin-
gle functional parameter of the combined end point will
also be assessed using the Hochberg correction for mul-
tiple testing [54]. The MRI end point will be evaluatedby comparing the mean number of lesions at 1 year, as-
suming a negative binomial model (α = 5%, two-sided
LRT). In both samples (RRMS and SPMS), analyses will
be performed on all secondary end points. Any deviation
from the planned statistical methods will be properly
documented in the study report.
Stopping Rules
Guidelines have been established to ensure that the
study will be stopped as soon as possible in the event of
occurrence of an unacceptable proportion of SAEs. The
method used follows a Bayesian approach [55,56]. It is
assumed that the number of events follows a binomial
distribution, and the a priori distribution of the prob-
ability of event is a β (1,1), which corresponds to an un-
informative uniform distribution. Table 6 shows the
experimental results that provide a posterior probability
of 90% or more of observing a percentage of SAEs in the
overall sample higher than an acceptable maximum,
established at 4%. Given the current number of recruited
patients, the values in Table 6 indicate the minimum
number of SAEs that should alert the investigators to as-
sess whether to continue the study.
Concomitant therapies
If not explicitly mentioned in the inclusion or exclusion
criteria, the concomitant therapies for chronic patholo-
gies not correlated with MS will be continued through-
out the study period. All drugs given to participants
during the study will be recorded in the e-CRF. All
pharmacological or rehabilitative treatments (motor
reeducation and balance, walking and cognitive training),
carried out during the study and in the six months pre-
vious randomization will be recorded in the e-CRF.
Changes considered in the regimen of treatments with
potentially relevant effects on the tested functions (for
example, changes in type and intensity of physiotherapy,
new assumption of antispastic drugs) will be recorded
and taken into account in the data analyses. The im-
plantation of a baclofen pump will lead to the classifica-
tion of the patient as “worsened.”
Monitoring of the study
The monitoring procedures will be entrusted to a CRO.
During the study, monitoring personnel will visit the
participating centers on a regular basis to verify com-
pleteness of the data, accuracy of completion of the data
collection forms, adherence to the study protocol and to
good clinical practice (GCP), and state of the enrollment
or any other problems. The treating neurologist will pro-
vide the monitors with full access to clinical data to con-
firm the consistency of the information recorded on the
e-CRF. All information relative to patient identity must
be kept confidential according to Italian law (D. Lvo 96/
Table 6 Safety results that provide a posterior probability
of 90% or more of observing a percentage of serious
adverse events in the overall sample higher than an
acceptable maximum (4%)
Number of serious adverse events Number of cumulative
patients in study
2 13 to 27
3 28 to 44
4 45 to 61
5 62 to 79
6 80 to 98
7 99 to 117
8 118 to 137
9 138 to 157
10 158 to 177
11 178 to 198
12 199 to 218
13 219 to 239
14 240 to 260
15 261 to 281
16 282 to 302
17 303 to 323
18 324 to 345
19 346 to 366
20 367 to 388
21 389 to 410
22 411 to 431
23 432 to 453
24 454 to 475
25 476 to 497
26 498 to 519
27 520 to 541
28 542 to 563
29 564 to 585
30 586 to 608
31 609 to 630
32 631 to 652
33 653 to 674
34 675 to 679
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by a conventional code to keep their personal and sensi-
tive information anonymous.Study reports
The scientific responsibility for monitoring the course of
the study will be entrusted to an independent data mon-
itoring committee (IDMC) and to the SC that will workin close contact with the DCC and the CRO. The IDMC
will receive a report to evaluate the progress and safety
of the study every 3 months in the first year and every 4
months from the second year on, and it will inform the
SC of any recommendations for an early interruption of
the study. The reporting form will be defined in collab-
oration with the DCC and the CRO, it will be approved
by SC and it will be produced by the CRO in a blinded
form. Only the IDCM and the party responsible for the
quality of the data may ask for an unblinded version of
the report. The IDMC will evaluate safety, also taking
into account early stopping rules. The IDMC will also
consider whether the proportion of negative venography
in the patients with positive echo Doppler results
exceeds the expected 10% proportion and will discuss
with the SC the possible implications for the conduct of
the study. Every 4 months the DCC will provide an
evaluation of study quality. Within 1.5 years after the
start of recruitment, the DCC member in charge of
monitoring study quality will provide a description of
preliminary results on the subset of patients with 1 year
of follow-up, allowing assessment of the validity of the
sample size calculations. This evaluation will be submit-
ted in blinded fashion to the IDMC for recommenda-
tions to the SC. During the study, the IDMC, in
collaboration with the SC, will assess new publications
on CCSVI and MS that might be relevant to the study
protocol.
Discussion
In this trial, we aim to evaluate the efficacy and safety of
angioplasty of extracranial veins for patients with RRMS
or SPMS as well as sonologic diagnosis of CCSVI. Such
a study may be seen as controversial because the patho-
physiological evidence of the cause-and-effect relation-
ship between CCSVI and MS is lacking. Had this been a
typical situation, without strong media pressure [57], a
phase III comparative randomized trial at this stage
probably would not have been justified and we would
have proceeded with a phase II study. However, a phase
II trial would likely have been done without a control
group and the sample sizes would have been too small,
given the variability of MS course, to indicate plausible
effects. It would thus add little to what we know from
observational studies and leave the question of efficacy
still in need of a rigorous phase III trial.
MS is widely considered an inflammatory autoimmune
disease; however, this remains a hypothesis, and in reality
the exact cause of MS remains unknown. The pharmaco-
logical treatments currently available for MS can modify,
to a limited degree and over the long term, the natural
history of the disease. However, they cause numerous
side effects and are, at the moment, not easily proposable
along the whole disease course, which corresponds to the
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for evaluating whether new drugs under review for ap-
proval or in the experimentation phase will be able to
change the natural history of MS. Thus it is understand-
able that a nonpharmacological treatment hypothesizing
an improvement in the clinical picture (that is, the inter-
vention proposed by Zamboni), arouses great expecta-
tions for a confirmation of its scientific validity.
The proponent group took into account that the end
points currently used in clinical pharmacological studies
have been criticized on both clinical and methodological
grounds [58,59]. For this reason, two primary end points
were identified, one defined by a set of clinical instru-
mental parameters related to specific functional deficits
experienced by patients with MS and the other one
based on MRI findings, both measured 12 months after
randomization. The decision to utilize two primary end
points emerged from various considerations. First, the
hypothesized effect of angioplasty for MS patients with
CCSVI does not allow exclusion of a clinical effect inde-
pendent of the incidence of active MRI lesions. On the
other hand, MRI parameters are largely utilized as indi-
cators of activity in clinical trials for MS and are consid-
ered robust with respect to any placebo effect. The
observation of a statistically significant advantage in only
one of the two end points (clinical or MRI) will be suffi-
cient to declare the study results in favor of the superior-
ity of angioplasty over sham procedure. In the event of
conflicting results (active treatment favored by one end
point and not favored by the other one), the combined
clinical end point will prevail. Second, the use of two
primary end points in this situation offers at least two
advantages: (1) If masking of both participants and
investigators succeeds, the demonstration of a significant
effect of the treatment on even only one of the two end
points would be sufficient to reject the hypothesis that
venous angioplasty is not active or efficacious in patients
with MS; and (2) in the event that failure of the masking
occurs, thus potentially weakening the evidence coming
from the clinical end point, the evaluation of the MRI
end point would maintain its validity entirely, thereby
permitting the study to conserve, even if only partially,
scientific and clinical usefulness.
A novel functional composite end point was defined to
assess the primary clinical end point. The reason for this
decision was that the EDSS [47], the most widely used
disability measure in clinical trials for MS, is an
ambulation-centered scale that does not take into ac-
count cognitive impairment or upper-arm or bladder
dysfunctions that are primary components of disability.
The EDSS is an ordinal nonlinear scale whose serial up-
ward changes of 0.5 or 1.0 points, confirmed at 3–6
months or unconfirmed, are commonly used in clinical
trials. However, changes of 0.5 points are invalid, even ifconfirmed at 3 or 6 months, and, similarly, 1-point
changes are not significantly more likely to occur for
worsening than for improvement [58]. When choosing
the indicators of the functional composite end point, we
took into account relevant parameters, that is, the preva-
lence and clinical relevance of impaired functions in MS,
objective and validated measures, and global feasibility
of the tests in terms of tolerance, time scales, costs and
necessary skills. Also, all tests are instrumental and thus
semiobjective, although prone to behavioral influences.
An extensive review of the literature was carried out,
and the specific skills and experience in the field of func-
tional testing of the various members of the working
group were taken into account. The choice was then
made after reflection and collegial discussion.
Each participating center is accredited as a MS center
by the National Health Service and employs professionals
with the following skills: neurology, neuroradiology, non-
invasive vascular diagnosis, vascular surgical radiology,
physiotherapy and psychometric testing. The staff par-
ticipating in the study are accredited for the ECD diagno-
sis of CCSVI, the venous angioplasty intervention and
the measurement of the functional end points.
This clinical trial will provide answers with regard not
only to the efficacy of venous angioplasty on the inflam-
matory component of MS but also about subjective
symptoms and functions, such as motor impairments,
sphincteral and visual deficits, fatigue, anxiety, depres-
sion and attention deficits, which are meaningful clinical
outcomes. In fact, an important part of patients’ expec-
tations, sustained and amplified by anecdotal data on
improvement of quality of life reported in the Zamboni
et al. study [34], has to do with precisely these aspects.
Trial status
Recruiting.
The present trial is registered (Clinical Trials Registra-
tion No. NCT01371760) and is supported by a grant of
€2,922,404 from Regione Emilia Romagna, Italy.
The study has been approved by either the Ethics Com-
mittees of the Promoter, Azienda Ospedaliera Universi-
taria di Ferrara (Ref No: 3/2011), or the Italian
participating centers: 1. San Carlo Borromeo Hospital,
Milano; 2. San Donato University Hospital-University of
Milano; 3. Foundation Neurological Institute C Besta,
IRCCS, Milan; 4. Istituto Auxologico Italiano, IRCCS-
University of Milano, Milano; 5. Hospital Maggiore della
Carità, Novara; 6. Sant’Antonio Hospital, Padova; 7. Uni-
versity Hospital of Ferrara; 8. Bellaria Hospital, Bologna;
9. Santa Maria delle Croci Hospital, Ravenna; 10. Careggi
University Hospital-University of Florence; 11. Hospital
Civitanova, Marche; 12. Cannizzaro Hospital, Catania;
13. Policlinico G. Rodolico-University Vittorio Emanuele,
Catania; 14. Villa Sofia-Cervello Hospital, Palermo.
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